Carlo Di Bona
Carlo Di Bona publishes mostly in Surgery, Pulmonary and Respiratory Medicine and Urology, on topics such as Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies and Prostate Cancer Diagnosis and Treatment.
- World rank
- #4,028,848 of 7,710,434 ranked researchers
- Rank in Switzerland
- #55,936 of 80,918
- Works
- 19
- Citations
- 174
- Citations per work
- 9.2
What does Carlo Di Bona research?
Carlo Di Bona's work is mostly in Medicine (81%), Health Professions (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1686.1%
- Medicine1580.8%
- Health Professions15.3%
- Everything else313.9%
- 1Surgery46% of their works
- 2Pulmonary and Respiratory Medicine25% of their works
- 3Urology5% of their works
- 4General Health Professions5% of their works
- 5Oncology4% of their works
- 6Obstetrics and Gynecology2% of their works
Research topics
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Urinary Bladder and Prostate Research
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
Which keywords describe Carlo Di Bona's research?
The keywords of their largest research topics: Immunotherapy, Molecular Characterization, Neoadjuvant Therapy, Bladder Cancer, Urothelial Carcinoma, Clinical Guidelines, Primary Urethral Carcinoma and Urachal Carcinoma.
- Preoperative Chemoradiotherapy
- Cholangiocarcinoma
- Lower Urinary Tract Symptoms
- Benign Prostatic Hyperplasia
- Renal Cell Carcinoma
- Epidemiology
- Radiation Therapy
- Genetic Mutations
- Urachal Carcinoma
- Clinical Guidelines
- Bladder Cancer
- Molecular Characterization
- Immunotherapy
- Neoadjuvant Therapy
- Urothelial Carcinoma
- Primary Urethral Carcinoma
- Prostate Cancer
- Prognostic Factors
- Screening
- Metastatic
- Androgen Receptor
- Genomic Profiling
- Biliary Tract Cancer
- Esophageal Carcinoma
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 24 words, with their numbers
- Immunotherapy203 topics
- Molecular Characterization172 topics
- Neoadjuvant Therapy152 topics
- Bladder Cancer131 topic
- Urothelial Carcinoma131 topic
- Clinical Guidelines92 topics
- Primary Urethral Carcinoma91 topic
- Urachal Carcinoma91 topic
- Prostate Cancer82 topics
- Genetic Mutations72 topics
- Prognostic Factors62 topics
- Radiation Therapy51 topic
- Screening51 topic
- Epidemiology42 topics
- Metastatic41 topic
- Renal Cell Carcinoma41 topic
- Androgen Receptor31 topic
- Benign Prostatic Hyperplasia31 topic
- Genomic Profiling31 topic
- Lower Urinary Tract Symptoms31 topic
- Biliary Tract Cancer21 topic
- Cholangiocarcinoma21 topic
- Esophageal Carcinoma21 topic
- Preoperative Chemoradiotherapy21 topic
Where does Carlo Di Bona work?
Carlo Di Bona's main affiliation in the publication record is Luzerner Kantonsspital, Switzerland.
How many publications and citations does Carlo Di Bona have?
OpenAlex counts 19 works and 174 citations for Carlo Di Bona, an h-index of 8, ranking #4,028,848 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Carlo Di Bona. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.